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ABSTRACT
Background: We hypothesized that immune-infiltrates were associated with 
superior survival, and examined a primary osteosarcoma tissue microarrays (TMAs) 
to test this hypothesis.
Methods: 129 patients (pts) with localized osteosarcoma treated within protocol 
ISG-OS1 were included in the study. Clinical characteristics, expression of CD8, CD3, 
FOXP3, CD20, CD68/CD163 (tumor associated macrophage, TAM), Tia-1 (cytotoxic 
T cell), CD303 (plasmacytoid dendritic cells: pDC), Arginase-1 (myeloid derived 
suppressor cells: MDSC), PD-1 on immune-cells (IC), and PD-L1 on tumoral cells 
(TC) and IC were analysed and correlated with outcome.
Results: Most of the cases presented tumor infiltrating lymphocytes (TILs) (CD3+ 
90%; CD8+ 86%). Tia-1 was detected in 73% of the samples. PD-L1 expression was 
found in 14% patients in IC and 0% in TC; 22% showed PD-1 expression in IC.
With a median follow-up of 8 years (range 1-13), the 5-year overall survival 
(5-year OS) was 74% (95% CI 64-85). Univariate analysis showed better 5-year 
OS for: a) pts with a good histologic response to neoadjuvant chemotherapy (p = 
0.0001); b) pts with CD8/Tia1 tumoral infiltrates (p = 0.002); c) pts with normal 
alkaline phosphatas (sALP) (p = 0.04). After multivariate analysis, histologic response 
(p = 0.007) and CD8/Tia1 infiltration (p = 0.01) were independently correlated with 
survival. In the subset of pts with CD8+ infiltrate, worse (p 0.02) OS was observed 
for PD-L1(IC)+ cases.
Conclusions: Our findings support the hypothesis that CD8/Tia1 infiltrate in 
tumor microenvironment at diagnosis confers superior survival for pts with localized 
osteosarcoma, while PD-L1 expression is associated with worse survival.
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INTRODUCTION
Ostesarcoma is a rare, aggressive sarcoma. 
Whereas there is an agreement that surgery, with adjuvant 
chemotherapy, is paramount for the primary therapy of the 
cancer, about 30% of patients without evident metastases 
at presentation will die of disease [1]. The prognosis is 
even poorer (10% survival at 5-years) in patients with 
synchronous metastases [1]. Therefore there is an urgent 
need to identify new targets, different risk groups and 
predictive factors for tailored treatment for each individual.
Various mechanisms have been proposed for the 
resistance of human solid tumors to immune recognition 
and obliteration, including the recruitment of regulatory T 
cells (T-reg), myeloid derived suppressor cells (MDSC) [2] 
and up-regulation of immune inhibitory ligands, such as 
the ligand of programmed cell death protein 1 (PD-L1) [3].
T-lymphocyte and antigen-presenting cells (APCs) 
interaction is in fact bi-directional and mediated by PD-
L1 and programmed cell death protein 1 (PD1) on APCs 
and on lymphocytes. PD-L1 is expressed also by several 
tumors [3].
PD1/PD-L1 pathway inhibitors such as 
pembrolizumab, nivolumab, atezolizumab have been 
approved from several solid tumors (melanoma, kidney, 
lung cancer, head and neck, Merkel cell tumors, Hodgkin’s 
lymphoma), and PD-L1 expression on tumoral cells (TC) 
or in immune-infiltrate (IC) has been associated with 
response to checkpoint inhibitors, in some cases [4], but 
PD-L1 expression predictive value remain controversial 
[5, 6]. Recently, anecdotal responses with pembrolizumab, 
nivolumab and also with nivolumab/pazopanib 
combination were reported in osteosarcoma patients [7–9]. 
These compounds interrupt PD-1/PD-L1 axis, impeding 
the PD-L1 mediated ‘tumor shield’ effect (Figure 1).
Few data on osteosarcoma microenvironment 
composition and the PD-1/PD-L1 expression are available, 
and most of the studies refer to small series with incomplete 
clinical information, inhomogeneous for stage (metastatic and 
localized patients), treatments and timing of biopsies [10].
Figure 1: Mechanisms for intratumoral programmed cell death ligand-1 (PD-L1) expression. Adaptive focal expression 
of PD-L1 by macrophages (CD68+/CD163+) occurs at the interface of tumor cell nests with immune infiltrates secreting pro-inflammatory 
factors such as interferon-γ. The ligation of PD-L1 on macrophage and, in some histotypes, on tumor cells, with programmed cell death 
protein 1 (PD-1) molecules will down-modulate T cell function, essentially creating a negative feedback loop that reduces antitumor 
immunity (the so called ‘tumor shield’ effect), eventually reducing CD8 tumoricidal function.
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The present study aim is to characterize the 
immune-infiltrates and PD-L1/PD-1 pathway in sample 
of chemo-naïve patients with localized osteosarcoma, 
treated according to the same protocol, in order to assess 
its prognostic implications and its potential role in cancer 
immune-evasion.
RESULTS
Tumoral microenvironment components prior 
chemotherapy (bioptic samples)
Eighty-six out of 129 cases analysed were evaluable 
for at least 7 markers and were included in the present study.
Most of the cases presented TILs (CD3+ 77/86, 
90%; CD8+ 74/86, 86%, CD20+ 25/86, 29%), while 
FOXP3+ (Treg) were detected in 28/86 (33%) of the 
patients (Table 1; Figure 2). Tia-1 was detected in 57/78 
(73%) of the samples. TAMs (CD163 positive) were 
observed in the microenvironment in 47/70 (67%) of 
the patients, while 31/74 (37%) patients presented also 
high levels of CD68 positivity (Table 1; Figure 2). Only 
3/78 (4%) and 16/78 (21%) cases presented CD303+ and 
Arginase-1+ cells. PD-L1 expression was found in 12/86 
(14%) patients in IC and 0/86 (0%) in TC; 19/86 (22%) 
showed PD-1 expression in IC (Table 1; Figure 2).
Survival analysis
With a median follow-up of 8 years (range 1-13), 
the 5-year OS was 74% (95% CI 64-85). Univariate 
analysis showed better 5-year OS for good responders 
(good 89% vs poor 57%, p = 0.0001), for cases with 
CD8/Tia1 tumoral infiltrates (CD8+/Tia1+ 81% vs CD8+/
Tia1- 60% vs CD8-/Tia1- 45%, p = 0.002) and patients 
with normal AP at baseline (AP normal 85% vs AP 
high 44%, p = 0.04) (Table 2, Figure 3). No statistically 
significant difference was observed in 5-year OS 
according to PD-1, FOXP3, CD68, CD20, Arginase-1, 
CD303, CD163 expression in microenvironment, and 
age, gender or LDH, while PD-L1 (IC) positive cases 
had a non-significant inferior 5-year OS (PD-L1+ 58% 
vs PD-L1- 77%, p = 0.14) (Table 2). 
After multivariate analysis, good histologic 
response (p = 0.007) and a CD8+/Tia1+ lymphocytic 
infiltrate (0.05) were independently associated with better 
survival (Table 3).
Since PD-L1(IC) is a marker of cytotoxic function 
exhaustion, we investigated if PD-L1 expression could 
influence survival in the subgroup of patient with CD8+ 
lymphocytes: at univariate analysis the 5-year OS was 
82% (95%CI 73%-92%) in case of PD-L1 negative and 
58% (95% CI 34%-78%) in positive PD-L1 (p = 0.03) 
(Figure 3). At the multivariate analysis in this subgroup, 
lack of PD-L1 was and independent prognostic factor for 
longer survival (p = 0.04) (Table 4).
Tumoral microenvironment components post-
induction chemotherapy (surgical samples)
Based on multivariate analysis results on pre-
treatment samples, a post-hoc analysis on CD8 and Tia1 
was performed.
Due to post-treatment changes 33/86 patients were 
assessable after treatment (excluding 53 patients with 
massive necrosis and no tumor).
Chemotherapy-induced changes of CD8+ TILs 
were as follow: all patients with score 0 (5 cases) were 
unchanged, the proportion of patients with score 1 
decreased: 19/33 (58%) pre-chemotherapy, 14/33 (42%) 
post-treatment; and the proportion of patients with a score 
2/3 increased: 9/33 (27%) to 12/33 (36%) (p 0.5).
A survival analysis according to presence of CD8+ 
/Tia1+ infiltrates presence in the surgical samples after 
induction-chemotherapy, confirmed their prognostic role: 
5- year OS was 78% (CI% 51-100) for CD8+/Tia1+ (22 
patients), 64% (CI%43-84) for CD8+/Tia1- (9 patients) 
and none was alive with CD8-/Tia1- (2 patients) (p 0.05) 
(Supplementary Figure 1).
DISCUSSION
The role of microenvironment in tumor immune 
escape is well recognized. Several studies addressed the 
role of tumor microenvironment in pathobiology and its 
impact on survival of osteosarcoma [11–15], however 
none is specific for osteosarcoma in the localized stage, 
nor compared the prognostic power of immune-infiltrate 
Table 1: Immunological characterization of tumor microenvironment in 86 patients with localized osteosarcoma
CD3
n (%)
CD8
n (%)
CD20
n (%)
FOXP3
n (%)
Tia1
n (%)
CD68*
n (%)
CD163
n (%)
CD303
n (%)
Arg-1
n (%)
PD-L1
(TC)
n (%)
PD-1
(IC)
n (%)
PD-L1
(IC)
n (%)
Pos 77 (90) 74 (86) 25 (29) 28 (33) 57 (73) 31 (37) 47 (67) 3 (4) 16 (21) 0 (0)
19 
(22)
12 
(14)
Neg 9 (10) 12 (14) 61 (71) 58 (67) 21 (27) 53 (63) 23 (33) 75 (96) 62 (79)
86 
(100)
67 
(78)
74 
(86)
Arg-1: Arginase-1; TC: tumor cells; IC: immune cells; * CD-68: Pos: high level expression; neg: low level expression.
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with the other validate prognostic factor routinely used in 
clinical practice [16, 17],
The present study, including patients with 
osteosarcoma in a localized stage, and treated within 
the same protocol [16], demonstrated an independent 
prognostic role of CD8+ and Tia1 lymphocytes.
The first study demonstrating the association 
between CD8 infiltrate and cancer specific survival 
was published in 2001 [18], and similar findings were 
subsequently confirmed among many histotypes [19, 20].
In the sarcoma field both a series of 33 
ostesarcoma, including metastastic and localised 
patients [11], and a large soft tissue sarcoma French 
study, including several histotypes and also low grades 
lesions, failed to demonstrate a prognostic role for CD8+ 
lymphocytes [21].
The results of our study are in contrast with those 
data [11, 21], in fact a strong advantage in terms of 
survival has been observed in patients with CD8+ infiltrate.
To investigate the differentiation state of tumor-
infiltrating T cells, tissues were analyzed for Tia1 
expression, which is a marker of cytotoxic function: the 
prognostic significance of CD8+ cells was even more 
relevant when the tumor infiltrate was characterized by 
the concomitant presence of Tia1+ lymphocytes. Tia1+ 
lymphocytes might represent a more efficient subset of 
CD8+ effector cells, playing an important role in immune-
surveillance of osteosarcoma [22].
The prognostic role of cytotoxic TILs CD8/
Tia1 was also confirmed after induction chemotherapy, 
while chemotherapy does not seem to induce significant 
changes in CD8+ TILs: all cases with no CD8+ TILs 
prior chemotherapy, were confirmed negative after 
chemotherapy, while a slight increase on score severity (1 
to 2/3) was observed.
In our study, the rate of PD-L1 expression in IC 
was 14%. Previous studies on osteosarcoma samples 
reported a higher rate of positive expression of PD-L1(IC) 
ranging from 25% [11] to 74% [10]. This difference might 
be related to the heterogeneity of the cases examined, 
being many of them metastatic, while our patients all had 
localized disease. In fact, it is well known that PD-L1 
expression increases in advanced stages of the diseases 
as reported by Sundara Y et al: 13% in primary tumours, 
25% in local relapses tissue and 48% in metastatic (p = 
0.002) [12].
Figure 2: Tumor microenvironment in localized osteosarcoma. Immunohistochemical expression of CD3, CD8, CD20 
(T tumor infiltrating lymphocytes: TILs), Tia-1 (cytotoxic T cell), FOXP3 (T regulatory lymphocytes: T-regs), PD-1, PD-L1, CD68 
(tumor associated macrophages: TAM), BDCA-2/CD303 (plasmacytoid dendritic cells: pDC), Arginase-1 (myeloid derived suppressor 
cells: MDSC) proteins.
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Table 2: Univariate Analysis for Overall Survival (OS) in patients with localized osteosarcoma
Pts N. % 5-year OS 95% CI P-value
Overall 86 74.5 65-84
Age 0.9
 ≥ 18 years 27 74 57-90
 < 18 years 59 75 63-86
Sex 0.8
 Female 33 76 61-90
 Male 53 74 61-89
Histologic Response° 0.0001
 Good 45 89 80-98
 Poor 40 57 42-73
CD8 0.003
 Positive 74 78 69-88
 Negative 12 50 22-78
TIA-1 °° 0.008
 Moderate 14 86 67-100
 Focal 43 79 67-91
 None 21 52 31-74
CD8/ Tia1 °° 0.002
 Positive / Positive 57 81 70-91
 Positive / Negative 10 60 30-90
 Negative / Negative 11 45 16-75
CD3 0.07
 Positive 77 78 69-87
 Negative 9 44 12-77
FOXP3 * 0.13
 Positive 28 75 54-93
 Negative 56 73 64-85
PD-1 (IC) 0.6
 Positive 19 74 54-93
 Negative 67 74 64-85
PD-L1 (IC) 0.14
 Positive 12 58 30-86
 Negative 74 77 67-87
LDH °° 0.15
 Normal 60 78 68-89
 High 18 61 39-84
sAP 0.04
(Continued )
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In our study a trend towards an inferior survival 
for positive PD-L1(IC) patients was observed. Other 
reports were able to demonstrate a significantly inferior 
event-free-survival (EFS) for osteosarcoma patients 
with positive PD-L1(IC) [11]. A prognostic role for PD-
L1 was also confirmed by Kim et al, at RNA level [10]. 
Interestingly, in our series, the PD-L1(IC) expression 
has a prognostic significance at multivariate analysis in 
the subgroup of patients with CD8+ immune-infiltrate. It 
might be hypothesised that “PD-L1”-mediated immune-
suppression negatively influences CD8+ lymphocytes 
function (Figure 1). In addition, it was shown that tumor 
response to PD-L1 or PD-1 inhibition is directly related 
to both the level of PD-L1 expression and lymphocytic 
infiltration of the tumor [23–25].
None of the patients had PD-L1 on tumor cells, as 
shown for other histotypes, such as colon rectal and gastric 
carcinoma [26, 27]. About 7% of osteosarcoma presented 
Pts N. % 5-year OS 95% CI P-value
 Normal 48 85 75-95
 High 38 64 48-80
Arginase-1 ** 0.3
 Positive 16 81 62-100
 Negative 61 70 59-82
CD303 °° 0.9
 Positive 3 67 13-100
 Negative 75 73 63-83
CD68 * 0.1
 High 31 84 71-99
 Low 53 67 54-80
CD163 *** 0.17
 Positive 47 81 70-92
 Negative 23 56 36-77
° Not available in 1 patient; °° non available in 8 patients; * not available in 2 patients; ** not available in 7 patients; *** not 
available in 16 patients
Figure 3: Survival and immune-infiltrate. (A) 5-year overall survival according to CD8/Tia1 expression in localized osteosarcoma; 
(B) 5-year overall survival according to PD-L1 expression in patients with CD8+ localized osteosarcoma.
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PD-L1 in the neoplastic clone in the study by Koirala et 
al [11], while head and neck squamous cell carcinoma, 
melanoma, breast and kidney cancer frequently express 
PD-L1 on the surface of tumour [4, 28]. Such variable 
expression among different studies may reflect the variable 
susceptibility of tumour cells and infiltrating immune 
cells to cytokines and other stromal factors in the tumour 
milieu [5]. In fact there are two distinct type of PD-L1 
expression: the first is a constitutive (innate) expression 
on tumoral cells membranes, with an homogenous patter; 
the second is adaptative, and can be found both on tumoral 
cells or in macrophage [5].
In 67% of the cases we found CD163+ macrophages 
in microenvironment. CD163 was shown to be a useful 
marker for M2-like macrophages, which have a “pro-
tumoral” activity, in contrast with M1-like macrophages 
characterized by a “tumoricidal” activity [29].
In our series no difference in survival according 
with presence of TAMs, characterized by both CD163 
and CD68 expression, was observed (CD163+ 81% vs 
Table 3: Multivariate Analysis for Overall Survival (OS) in patients with localized osteosarcoma
Variable RR 95% CI P
CD8/Tia1
 Positive/Positive 1 0.05
 Positive/Negative 1.8 0.7-5.2 0.2
 Negative/Negative 3.1 1.2-7.8 0.01
Histologic Response
 Poor 1 0.007
 Good 0.27 0.1-0.7
sPA
 Normal 1 0.2
 High 1.75 0.8-3.9
Figure 4: Proposal for ‘Immune-infiltrate based treatment algorithm’ for localized osteosarcoma.
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CD163- 56%, p = 0.17), while in other osteosarcoma series 
a prognostic role of TAMs was suggested [13, 14]. This 
might be explained by different statistical analysis design 
and different stages of patients included [13, 14].
Our data suggest a role of immune-infiltrate in 
progression of localized osteosarcoma, and might support 
the use of immune-modulating agents in the treatment 
of this tumor. Of interest, mifamurtide, a modulator 
of innate immunity, which increases a wide variety of 
immunomodulatory molecules [15] and favours CD8 
and NK cell activation [30], has been approved by EMA 
for the treatment of patients with localized high-grade 
osteosarcoma based on the results of a randomized trial [31].
In conclusion, CD8/Tia1 citotoxic T-lymphocytes 
emerge as an important player in anti-tumor immune 
response. Also, this study highlights the prognostic role 
of tumor microenvironment in the setting of localized 
osteosarcoma. The data are interesting and intriguing, but 
a clinical application requires confirmations in other series 
(Figure 4).
MATERIALS AND METHODS
Pre-treatment (bioptic samples)
After EC approval, tissue samples obtained from 
biopsies performed prior chemotherapy in 129 patients 
were collected. Patients were prospectively treated at 
Istituto Ortopedico Rizzoli from 04/2001 to 11/2006 within 
protocol ISG-OS1, with surgery and a chemotherapy based 
on methotrexate, cispaltin, adriamicyn and ifosfamide as 
described [16].
The clinical characteristics of the patients were the 
following: the median age was 16 years (range 4-39 years), 
with paediatric patients (59/86, 67%) and male gender 
(53/86, 62%) being most represented. High LDH levels 
and high AP at baseline were detected in 36/86 (42%) 
and 18/86 (21%) of patients respectively. All patients 
underwent neo-adjuvant chemotherapy and surgery as per 
protocol. A good pathologic response (≥90% necrosis) was 
achieved by 45/86 (52%) of the patients.
All samples underwent decalcification as previously 
described [17].
For tissue microarray (TMA) construction, a slide 
stained with hematoxylin and eosin was prepared from 
each formalin-fixed, paraffin-embedded (FFPE), and 
representative tumor regions were morphologically identified 
and marked on each slide. Tissue cylinders with a diameter 
of 1.0 mm were punched from the marked areas of each 
block and brought into a recipient paraffin block. Five TMAs 
were constructed. Each tumor sample was represented by a 
minimum of 1 core to a maximum of 5 cores.
From TMA blocks, 4 micron-sections were cut. This 
histological sections were coloured with haematoxylin 
eosin and the tumor microenvironment was characterized 
by applying antibodies directed against fixation resistant 
epitopes of CD68 (tumor associated macrophages: TAM), 
CD3, CD8, CD20 (T tumor infiltrating lymphocytes: 
TILs), FOXP3 (T regulatory lymphocytes: T-regs), Tia-
1 (cytotoxic T cell), BDCA-2/CD303 (plasmacytoid 
dendritic cells: pDC), Arginase-1 (myeloid derived 
suppressor cells: MDSC) proteins. PD-1 expression on 
immune-cells (IC), and PD-L1 on both tumour cells (TC) 
and IC was also investigated. The antibody reactivity, 
source as well as the antigen retrieval protocols were 
reported in Supplementary Table 1.
A semi-quantitative score from 0 to 3 was assigned 
to immune infiltrates: 0 = “none”: no immune infiltrates; 
1 = “focal”: mostly perivascular in tumor with some intra-
tumoral extension; 2 = “moderate”: prominent extension 
of immune infiltrates away from perivascular areas and 
amongst tumor cells); 3 = “severe” (immune infiltrates 
obscuring tumor) [4]. Pathologists were blinded to clinical 
information.
Only cores with tumoral component were included 
in the analysis. The immunehistochemical scores were 
Table 4: Multivariate Analysis for Overall Survival in patients with CD8+ localized osteosarcoma
Variable RR 95% CI P
PD-L1
 Negative 1 0.04
 Positive 2.8 1-7.4
Histologic Response
 Poor 1 0.02
 Good 0.3 0.1-0.9
sPA
 Normal 1 0.5
 High 1.4 0.5-3.8
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generally concordant among cores of the same patient, in 
case of heterogeneity the highest score was considered for 
the analysis.
For survival analysis samples were classified as 
negative (immunostaining = 0) or positive (immunostaining 
= 1 to 3) for all markers except: CD68+ cases that were 
classified in high expressing (severe and moderate 
expression) and low expressing (focal expression). 
Score for PD-L1 expression in TC: specimens with >5% 
membranous expression were considered positive.
The following factors were correlated with overall 
survival (OS): age (pediatric < 18 years vs adult ≥ 18 
years), gender, LDH and phosphatase alkaline (PA) 
levels at baseline (normal vs high), pathologic response 
(good: chemotherapy-induced tumor necrosis ≥ 90%; 
poor: chemotherapy-induced tumor necrosis < 90%) [17], 
tumoral microenvironment components, PD-1 expression 
on IC, and PD-L1 both on TC and IC.
OS was estimated according to the Kaplan and Meier 
method with their respective 95% confidence intervals 
(CI) and calculated from the first day of chemotherapy 
administration to death or last follow-up visit.
Post-induction chemotherapy (surgical samples)
In 86/129 patients, FFPE from tumoral masses 
surgically resected, after neoadjuvant chemotherapy, were 
collected. The full slides sections from FFPA were investigate 
by immunohistochemistry for CD8+ and Tia1 expression.
The following factors were correlated with overall 
survival: tumoral microenvironment components (CD8 
and Tia1).
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